IP Library › Granted Patent US 11,701,448
Granted Patent B2
US 11,701,448 · App. 17/002,399 · Granted Jul 18, 2023

Powder for achieving hemostasis

Inventors: Gerald Fredrickson (Westford, MA); Amanda L. Smith (Boston, MA); Andrew Pic (Northborough, MA); Sophia Gervasio (Coventry, RI); Lauren Lydecker (Millbury, MA)
Assignee: Boston Scientific Scimed, Inc.
A61L26/0023A61K31/722A61L26/008A61L26/0066A61L31/042A61L31/16A61L2300/232A61L2300/418A61L2300/60A61L2400/04A61M25/09A61M2025/091A61M2202/064A61M2210/1042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,701,448
App. No.
17/002,399
Granted
Jul 18, 2023
Kind
B2
Abstract

In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Claims (29)

1. A method of treating a tissue site comprising:

administering a composition to the tissue site;

wherein the composition includes a powder that comprises first particles comprising chitosan or a chitosan salt and second particles that comprise a crosslinking agent, wherein the crosslinking agent is a derivatized polymer selected from an epoxy derivatized polymer, an acrylate derivatized polymer, or a genipin derivatized polymer.

2. The method of claim 1 , wherein the composition is applied via a catheter.

3. The method of claim 1 , wherein the composition is fluidized in a gas to form a fluidized powder and blown onto the tissue site.

4. The method of claim 3 , wherein the gas is CO 2 .

5. The method of claim 3 , wherein the fluidized powder is applied using a catheter and wherein the fluidized powder exits the catheter at a velocity ranging from 15 m/s to 50 m/s.

6. A composition comprising:

first particles comprising chitosan or a chitosan salt; and

second particles comprising a crosslinking agent, wherein the crosslinking agent is selected from an epoxy derivatized polymer, an acrylate derivatized polymer, a genipin derivatized polymer, a multifunctional epoxy, acrylate, or genipin.

7. The composition of claim 6 , wherein the crosslinking agent is the epoxy derivatized polymer or the acrylate derivatized polymer.

8. The composition of claim 6 , wherein the first particles comprise a chitosan salt, wherein the chitosan salt comprisesa chitosan halide, a chitosan salt of an organic mono-acid, or a chitosan salt of an organic diacid.

9. The composition of claim 6 , wherein the epoxy derivatized polymer is epoxy derivatized chitosan, the acrylate derivatized polymer is acrylate derivatized chitosan, and the genipin derivatized polymer is genipin derivatized chitosan.

10. A method of treating or preventing bleeding at a tissue site comprising applying the composition of claim 6 to a gastrointestinal tract through an endoscope.

11. The method of claim 10 , wherein the composition is fluidized in a gas to form a fluidized powder composition and blown onto the tissue site.

12. The method of claim 11 , wherein the gas is CO 2 .

13. The method of claim 11 , wherein the fluidized powder exits the endoscope at a velocity ranging from 15 m/s to 50 m/s.

14. A composition comprising:

first particles comprising a modified chitosan selected from an aldehyde modified chitosan, epoxy modified chitosan, chitosan modified with unsaturated groups, chitosan derivatized with a multifunctional epoxide, acrylate modified chitosan, or thiol-modified chitosan; and

second particles comprising a covalent crosslinking agent;

wherein the composition is in the form of a powder; and

wherein the covalent crosslinking agent is a molecule having a plurality of unsaturated groups when the first particles comprise thiol-modified chitosan.

15. The composition of claim 14 , wherein the molecule having a plurality of unsaturated groups comprises a hydrophilic polymer having unsaturated end groups.

16. The composition of claim 14 , wherein the covalent crosslinking agent is a hydrophilic polymer having terminal carboxylic acid groups or terminal amine groups when the first particles comprise aldehyde modified chitosan, epoxy modified chitosan, chitosan modified with unsaturated groups, chitosan derivatized with a multifunctional epoxide, acrylate modified chitosan; and

wherein the covalent crosslinking agent is a molecule including an acrylate-terminated hydrophilic polymer when the first particles comprise thiol-modified chitosan.

17. A method of treating or preventing bleeding at a tissue site comprising applying the composition of claim 14 to a gastrointestinal tract through an endoscope.

18. The method of claim 17 , wherein the composition is fluidized in a gas to form a fluidized powder and blown onto the tissue site.

19. The method of claim 18 , wherein the gas is CO 2 .

20. The method of claim 18 , wherein the fluidized powder exits the endoscope at a velocity ranging from 15 m/s to 50 m/s.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2020
From: FREDRICKSON, GERALD; SMITH, AMANDA L.; PIC, ANDREW; GERVASIO, SOPHIA; LYDECKER, LAUREN
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 053597/0309 →
Continuity (3)
Continuation 16245780 · Jan 11, 2019
Provisional Application 62616751 · Jan 12, 2018
Related Publication 20200384148A1 · Dec 10, 2020
Cited By (1)
US 12,303,636